Impact of Comorbidities on Treatments and Outcomes of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

ABSTRACT:

Aim

Treatment recommendations for systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) have evolved from initial monotherapy to upfront combination therapy with agents, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors and prostanoids. In the presence of comorbidities, such as heart and lung disease, some clinicians have favoured monotherapy due to concerns about worsening ventilation-perfusion mismatch. We sought to evaluate whether comorbidity burden impacts prescribing practices, quality of life and survival in SSc-PAH.

Methods

We analysed prospectively collected data from participants recruited to the Australian Scleroderma Cohort Study (ASCS) between 2007 and 2024. Participants were included if they had PAH confirmed by right h

SUBMITTER: Lim L 

PROVIDER: S-EPMC12602041 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature